Novogene, the leading global provider of genomic services and solutions, has entered into an agreement with Illumina to purchase ten additional NovaSeq™ X Plus Systems, Illumina’s latest next-generation sequencing platform. This announcement cements company’s position as one of the leading global sequencing providers.
As an early adopter of the NovaSeq X Plus System, Novogene has deployed the platform across its laboratories in United States, United Kingdom and China from its launch in April 2023. By leveraging the platform’s high throughput, increased capacity and cost efficiency, the company has been able to provide sequencing at scale across a broad range of services to its global client base. This investment enables to optimize its regional service capabilities worldwide, ensuring consistent, high-quality, and cost-effective services for scientists around the world.
Susan Tousi, the Chief Commercial Officer of Illumina, indicates: “We take immense pride in our collaboration with Novogene, the global leader in commercial services, as we strive to broaden the scope of genomics through our revolutionary NovaSeq X Plus. Our enduring partnership with Novogene has spanned over a decade, during which both companies have worked relentlessly to democratize access to genomics worldwide. We have utmost confidence in Novogene’s continued commitment to providing genomics researchers globally with reliable, swift, and cost-effective Next-Generation Sequencing (NGS) services.”
Novogene’s longstanding partnership with Illumina started when the company became one of the first users of Illumina’s high-throughput sequencing system, HiSeq X Ten. Over the last decade, the company has consistently been among the first to adopt Illumina’s new platforms, from HiSeq 2000/2500/4000, to MiSeq, NextSeq 500, NovaSeq 6000, and now NovaSeq X Plus. The rapidly growing market for next generation sequencing, coupled with constant advances in technology, has led to a close collaboration between Novogene and Illumina.
Dr. Ruiqiang Li, the Chief Executive Officer of Novogene, comments: “Throughout our journey, Illumina has remained a pivotal partner for Novogene. Over a decade of collaboration, we’ve witnessed remarkable growth together. Illumina’s industry leading technology provides the foundation for breakthroughs in cutting-edge research. Novogene, drawing upon its extensive project experience, translates and applies these innovations worldwide. Currently operating in over 90 countries across six continents, Novogene’s global presence is a testament to the strong alliance between our two companies, driving the industry forward and fostering continuous development.”
In recent years, Novogene has embraced the latest technologies and expanded the applications and services available on these platforms, including PacBio’s third-generation sequencer Revio, and Thermo Fisher’s Orbitrap Astral high-resolution mass spectrometer. The company deploys across multiple laboratories at global network, and these cutting-edge instruments broaden the range of services and applications available to the global scientific community.
Novogene remains dedicated to its customer-centric approach and its commitment to collaborating with global leaders like Illumina to empower life science research. The company continues to strive to be your trusted genomics partner.
The field is required.